The US Food and Drug Administration labeling accompanying the prescription oral THC drug dronabinol (trade name Marinol) acknowledges that habitual consumers of THC become acclimated and tolerant to the substance’s effects of psychomotor skills. Posted information online at FDA.gov ) states, “Patients receiving treatment with MARINOL® Capsules should be specifically warned not to drive, operate machinery, or engage in any hazardous activity until it is established that they are able to tolerate the drug and to perform such tasks safely.” Note, the label does not say ‘Never drive after consuming Marinol.’ Further, it may be argued that subjects would be as likely, if not more likely, to become similarly tolerant to the effects of inhaled THC, since the latter contains compounds (e.g., cannabidiol) that temper some of the mood-altering effects of THC whereas these compounds are not present in Marinol. Further, Marinol is consumed orally, which often results in longer and more potent periods of onset compared to inhaled THC. Paul Armentano @NORML
Posted on: Mon, 04 Aug 2014 20:58:54 +0000
Trending Topics
Recently Viewed Topics
© 2015